What is HC Wainwright’s Estimate for Zymeworks Q3 Earnings?

Zymeworks Inc. (NASDAQ:ZYME) – HC Wainwright lowered their Q3 2026 earnings estimates for Zymeworks in a research note issued on Wednesday, August 5th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of $2.09 for the quarter, down from their prior forecast of $2.17. HC Wainwright has a “Buy” rating and a $51.00 price target on the stock. The consensus estimate for Zymeworks’ current full-year earnings is $1.36 per share.

Zymeworks (NASDAQ:ZYME) last released its earnings results on Tuesday, March 31st. The company reported ($0.59) earnings per share (EPS) for the quarter. The business had revenue of $2.41 million for the quarter. Zymeworks had a negative return on equity of 37.97% and a negative net margin of 126.92%.

Other research analysts have also issued research reports about the company. Citigroup reaffirmed a “buy” rating on shares of Zymeworks in a report on Tuesday, June 30th. Wells Fargo & Company boosted their target price on shares of Zymeworks from $34.00 to $37.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a research note on Friday, July 17th. Finally, Truist Financial increased their price target on shares of Zymeworks from $28.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zymeworks currently has an average rating of “Moderate Buy” and a consensus price target of $37.89.

Zymeworks Price Performance

ZYME opened at $23.50 on Thursday. Zymeworks has a 12 month low of $11.51 and a 12 month high of $29.75. The stock has a market capitalization of $1.72 billion, a P/E ratio of -17.15 and a beta of 1.15. The business has a 50 day simple moving average of $24.07 and a 200-day simple moving average of $24.46.

Hedge Funds Weigh In On Zymeworks

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd purchased a new stake in Zymeworks during the fourth quarter worth $37,000. Quarry LP purchased a new position in shares of Zymeworks in the third quarter valued at $50,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Zymeworks by 25.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,637 shares of the company’s stock worth $96,000 after buying an additional 731 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Zymeworks by 29.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock worth $62,000 after buying an additional 1,131 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new stake in shares of Zymeworks in the 4th quarter worth about $205,000. 92.89% of the stock is owned by institutional investors and hedge funds.

Zymeworks announced that its Board of Directors has approved a share buyback plan on Thursday, May 14th that allows the company to repurchase $125.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 7% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its shares are undervalued.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.